Fingolimod significantly reduced brain volume loss in patients with relapsing-remitting multiple sclerosis: 4-year data from FREEDOMS extension study

被引：0
|
作者：
Radue, E.
Kappos, L.
O'Connor, P.
Polman, C.
Hohlfeld, R.
Calabresi, P.
Selmaj, K.
de Vera, A.
Sfikas, N.
Zhang-Auberson, L.
Francis, G.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[4] Univ Munich, Munich, Germany
[5] Johns Hopkins Multiple Sclerosis Ctr, Baltimore, MD USA
[6] Med Acad Lodz, Lodz, Poland
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [21] Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study
    Filippi, Massimo
    Pagani, Elisabetta
    Turrini, Renato
    Bartezaghi, Marta
    Morra, Vincenzo Brescia
    Borriello, Giovanna
    Clerici, Valentina Torri
    Mirabella, Massimiliano
    Pasquali, Livia
    Patti, Francesco
    Totaro, Rocco
    Gallo, Paolo
    Rocca, Maria A.
    JOURNAL OF NEUROLOGY, 2024, : 6181 - 6196
  • [22] Fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis - ASSESS study results
    Cree, B. A.
    Goldman, M. D.
    Corboy, J. R.
    Singer, B.
    Fox, E.
    Arnold, D. L.
    Ford, C.
    Weinstock-Guttman, B.
    Bar-or, A.
    Mientus, S.
    Sienkiewicz, D.
    Zhang, Y.
    Karan, R.
    Tenenbaum, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 163 - 163
  • [23] The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis
    Derfuss, T.
    Sastre-Garriga, J.
    Montalban, X.
    Rodegher, M.
    Wuerfel, J.
    Gaetano, L.
    Tomic, D.
    Azmon, A.
    Wolf, C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (01)
  • [24] A Systematic Literature Review of Brain Volume Loss and Disability or Cognition Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis
    Benjumea, D.
    Janeczko, P.
    Callahan, P.
    Amari, D.
    Silva, D.
    Tencer, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1138 - 1138
  • [25] Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study
    Kappos, Ludwig
    Radue, Ernst-Wilhelm
    O'Connor, Paul
    Polman, Chris
    Hohlfeld, Reinhard
    Calabresi, Peter
    Selmaj, Krzysztof
    Agoropoulou, Catherine
    Jin, James
    Zhang-Auberson, Lixin
    Francis, Gordon
    NEUROLOGY, 2012, 78
  • [26] Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY
    Nixon, R.
    Eckert, B.
    Cutter, G.
    Mercier, F.
    Francis, G.
    Kappos, L.
    JOURNAL OF NEUROLOGY, 2012, 259 : S68 - S68
  • [27] Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
    Khatri, Bhupendra
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kappos, Ludwig
    Montalban, Xavier
    Pelletier, Jean
    Stites, Tracy
    Wu, Stacy
    Holdbrook, Fred
    Zhang-Auberson, Lixin
    Francis, Gordon
    Cohen, Jeffrey A.
    Cohen, J.
    Barkhof, F.
    Comi, G.
    Hartung, H.P.
    Khatri, B.
    Montalban, X.
    Pelletier, J.
    Easton, D.
    Calandra, T.
    DiMarco, J.
    Hudson, L.
    Kesselring, J.
    Laupacis, A.
    Temkin, N.
    Weinshenker, B.
    Zarbin, M.
    Barkhof, F.
    Poppe, P.
    Luetic, G.
    Cristiano, E.
    Caceres, F.
    Garcea, O.
    Correale, J.
    Ballario, C.
    Piedrabuena, R.
    Pollard, J.
    Beran, R.
    Hodgkinson, S.
    Schwartz, R.
    Heard, R.
    King, J.
    Butzkueven, H.
    Maida, E.M.
    Vass, K.
    Franta-Elmer, C.
    Berger, T.
    Aichner, F.
    LANCET NEUROLOGY, 2011, 10 (06): : 520 - 529
  • [28] Betaferon® in Early Relapsing-remitting Multiple Sclerosis Surveillance Trial (BEST):: interim 2- and 4-year data
    Kappos, L.
    Pohlman, U.
    Achnichts, L.
    MULTIPLE SCLEROSIS, 2007, 13 : S49 - S49
  • [29] Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss in an early phase of the disease
    Opfer, Roland
    Schwab, Matthias
    Silva, Diego
    Bangoura, Sabine
    Biswas, Mousumi
    Krueger, Julia
    Spies, Lothar
    Gocke, Carola
    Gaser, Christian
    Ziemssen, Tjalf
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 270 - 271
  • [30] Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing-remitting multiple sclerosis: results from the phase 3 FREEDOMS II study
    Vollmer, T.
    Goodin, D.
    Jeffery, D.
    Kappos, L.
    Radue, E. -W.
    Rammohan, K.
    Reder, A. T.
    Agius, M. A.
    Cappiello, L.
    Stites, T.
    Li, B. B.
    Malhotra, M.
    von Rosenstiel, P.
    Calabresi, P. A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 438 - 439
12345